Trisubstituted amine compound

A method for treatment of a disease involving CETP selected from the group consisting of arteriosclerosis, dyslipidemia, coronary artery disease, and hypertension, which comprises administering an effective amount of a compound of the general formula I-B):

• wherein
• ZA is N or CH;
• A21A is an optionally substituted homocyclic group, an optionally substituted alkylsulfanyl group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted alkyl group, a nitro group, a hydroxy group, a cyano group, an optionally substituted alkenyl group, an optionally substituted heterocyclic group, an optionally substituted alkoxy group, a halogen atom, an amino group optionally substituted by 1 to 2 substituents, a carbamoyl group optionally substituted by 1 to 2 substituents, a carboxyl group or a hydrogen atom;
• R1A is a cyano group or an alkyl group optionally substituted by 1 to 3 halogen atoms;
• B′ is a group selected independently from an oxo group, a cyano group, a halogen atom, an optionally substituted alkylsulfanyl group, an optionally substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an amino group optionally substituted by 1 to 2 substituents, a hydroxy group, an optionally substituted heterocyclic group, an optionally substituted cycloalkoxy group, an optionally substituted cycloalkyl group, a carboxyl group, a carbamoyl group optionally substituted by 1 to 2 substituents, an optionally substituted alkyl group or an optionally substituted alkoxy group;
• pA is an integer of 0 to 3;
• D is a pyrimidinyl group, a pyridyl group, a phenyl group, a pyrimidinyloxy group, a tetrazolyl group or an oxazolidinyl group;
• D′ is a group selected independently from a halogen atom, an alkoxyalkyl group, an alkyl group substituted by 1 to 5 halogen atoms, an alkoxy group substituted by 1 to 5 halogen atoms, an alkenyl group, a carbamoyl group, a cycloalkyl group, a mono- or di-alkylaminoalkyl group, a mono- or di-alkylaminoalkoxy group, a carboxyl group, a hydroxy group, a cyano group, an oxo group, an alkyl group, a hydroxyalkyl group, an alkoxycarbonylalkyl group, a carboxyalkyl group, a morpholinylalkyl group, a phenylalkyl group, an alkanoyl group, a hydroxyalkanoyl group, an alkoxyalkanoyl group, an alkoxy group, a phenylalkoxy group, an alkoxycarbonyl group, a benzyloxycarbonyl group, a mono- or di-alkylamino group, a mono- or di-alkylcarbamoyl group, a mono- or di-alkylsulfamoyl group, an alkylsulfonyl group, a tetrazolyl group, a benzyloxyalkyl group, a cycloalkylalkyl group, a benzyloxy group, an alkoxyalkoxy group, a carboxyalkoxy group, a carboxyalkenyl group, an alkylcarbonylamino group, a carboxyalkoxyalkyl group, a morpholinyl group or a pyridylalkoxy group;
• qA is an integer of 0 to 3,
• or a pharmaceutically acceptable salt thereof, to a patient in need thereof.